CDK4/6抑制剂治疗激素受体阳性人表皮生长因子受体2阴性乳腺癌的研究进展

Progress of CDK4/6 inhibitors in treatment of hormone receptor-positive and human epithelial growth factor receptor 2-negative breast cancer

细胞周期蛋白依赖性激酶(CDK)4/6抑制剂联合传统内分泌治疗能显著改善激素受体阳性人表皮生长因子受体2阴性乳腺癌患者的无进展生存和总生存,但不同的药物、给药剂量、用药周期会给患者带来不同的疗效和安全事件。确认CDK4/6抑制剂对我国乳腺癌患者是否同样适用,既是国内临床医生关注的热点,也是实际诊疗工作中的需要。文章介绍了不同药物的经典临床试验及最新研究进展。

Cyclin-dependent kinase(CDK)4/6 inhibitors combined with traditional endocrine therapy can significantly improve the progression-free survival and overall survival of hormone receptor-positive and human epithelial growth factor receptor 2-negative breast cancer patients.But different drugs,dosage and medication cycle will also bring different efficacy and safety incidents to patients.At the same time,confirming whether CDK4/6 inhibitors are equally applicable to Chinese breast cancer patients is not only an academic hotspot concerned by domestic clinicians,but also a practical need in actual diagnosis and treatment.This article reviews the classic clinical trials of drugs and the latest research progress.